Companies:

Pharmacologic class:

Active ingredient:

Indication:

Adjunct to diet and exercise in type 2 diabetes as monotherapy, or with a sulfonylurea or insulin.

Pharmacology:

Glumetza extended-release tablets are designed to deliver metformin HCl to the upper GI tract, which may reduce GI side effects often seen with immediate-release products.

Clinical trials:

In a randomized, double-blind study, three Glumetza regimens were evaluated in the treatment of patients with type 2 diabetes. Patients were given Glumetza 1.5 g once daily, Glumetza 1.5 g per day in divided doses (500 mg in the am and 1 g in the pm), Glumetza 2 g once daily, or immediate-release metformin 1.5 g per day in divided doses (500 mg in the am and 1 g in the pm). Each of the Glumetza regimens were at least as effective as immediate-release metformin in all measures of glycemic control. The once-daily dosing regimen was shown to be as effective as the twice-daily dosing regimen of the immediate-release metformin formulation.

Next Article in Drug Update

Sign Up for Free e-newsletters

ClinicalAdvisor.com is for nurse practitioners and physician assistants, offering the latest information on diagnosing, treating, managing, and preventing medical conditions typically seen in the office-based primary-care setting.

Find all of the news and departments you love from the print issue archived for easy online access, along with special Web-only content.